In addition, pomegranate extract has been reported to inhibit AChE—a crucial pharmacological target in AD management, the β-site amyloid precursor protein cleaving enzyme 1 (BACE1), thus reducing Aβ42 production [72,73]. This evidence concerns the gene ACHE and Alzheimer disease.